scholarly journals Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients

2005 ◽  
Vol 12 (12) ◽  
pp. 1455-1457 ◽  
Author(s):  
Shan-Chwen Chang ◽  
Jann-Tay Wang ◽  
Li-Min Huang ◽  
Yee-Chun Chen ◽  
Chi-Tai Fang ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Longitudinal Analysis ◽  
Specific Antibody ◽  
Immunoglobulin G ◽  
Disease Onset ◽  
Blood Sampling ◽  
Sars Coronavirus ◽  
Serum Antibodies ◽  
Igg Antibody ◽  
Igm Antibody

ABSTRACT The serum antibodies to severe acute respiratory syndrome (SARS) coronavirus of 18 SARS patients were checked at 1 month and every 3 months after disease onset. All of them except one, who missed blood sampling at 1 month, tested positive for the immunoglobulin G (IgG) antibody at 1 month. Fifteen out of 17 tested positive for the IgM antibody at 1 month. The serum IgM antibody of most patients became undetectable within 6 months after the onset of SARS. The IgG antibody of all 17 patients, whose serum was checked 1 year after disease onset, remained positive.

scholarly journals Specific Immunoglobulin G Antibody Detected in Umbilical Blood and Amniotic Fluid from a Pregnant Woman Infected by the Coronavirus Associated with Severe Acute Respiratory Syndrome

2004 ◽  
Vol 11 (6) ◽  
pp. 1182-1184 ◽  
Author(s):  
Xiugao Jiang ◽  
Xing Gao ◽  
Han Zheng ◽  
Meiying Yan ◽  
Weili Liang ◽  
...  
Keyword(s):  
Pregnant Woman ◽  
Severe Acute Respiratory Syndrome ◽  
Amniotic Fluid ◽  
Immunoglobulin G ◽  
Maternal Blood ◽  
Sars Coronavirus ◽  
Umbilical Blood ◽  
Specific Immunoglobulin

ABSTRACT Specific immunoglobulin G antibody for severe acute respiratory syndrome (SARS) coronavirus was detected in maternal blood, umbilical blood, and amniotic fluid from a pregnant SARS patient. Potential protection of fetus from infection was suggested.

scholarly journals Longitudinal Change of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies in Patients with Coronavirus Disease 2019

2020 ◽  
Vol 222 (2) ◽  
pp. 183-188 ◽  
Author(s):  
Guoxin Zhang ◽  
Shuke Nie ◽  
Zhaohui Zhang ◽  
Zhentao Zhang
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Disease Onset ◽  
Immunoglobulin M ◽  
Longitudinal Change ◽  
Igg Antibody ◽  
Serological Tests ◽  
Significant Difference ◽  
Rapid Spread ◽  
Novel Coronavirus ◽  
Acid Test

Abstract Background A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently emerged and caused the rapid spread of coronavirus disease 2019 (COVID-19) worldwide. Methods We did a retrospective study and included COVID-19 patients admitted to Renmin Hospital of Wuhan University between 1 February and 29 February 2020. Antibody assay was conducted to detect COVID-19 envelope protein E and nucleocapsid protein N antigen. Results One hundred twelve patients were recruited with symptoms of fever, cough, fatigue, myalgia, and diarrhea. All patients underwent antibody tests. Fifty-eight (51.79%) were positive for both immunoglobulin M (IgM) and immunoglobulin G (IgG), 7 (6.25%) were negative for both antibodies, 1 (0.89%) was positive for only IgM, and 46 (41.07%) were positive for only IgG. IgM antibody appeared within a week post–disease onset, lasted for 1 month, and gradually decreased, whereas IgG antibody was produced 10 days after infection and lasted for a longer time. However, no significant difference in levels of IgM and IgG antibodies between positive and negative patients of nucleic acid test after treatment was found. Conclusions Our results indicate that serological tests could be a powerful approach for the early diagnosis of COVID-19.

scholarly journals Recombinant Protein-Based Assays for Detection of Antibodies to Severe Acute Respiratory Syndrome Coronavirus Spike and Nucleocapsid Proteins

2007 ◽  
Vol 14 (3) ◽  
pp. 331-333 ◽  
Author(s):  
Lia M. Haynes ◽  
Congrong Miao ◽  
Jennifer L. Harcourt ◽  
Joel M. Montgomery ◽  
Mai Quynh Le ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Recombinant Protein ◽  
Sensitivity And Specificity ◽  
Immunoglobulin G ◽  
High Sensitivity ◽  
Kinetic Studies ◽  
Spike Protein ◽  
Sars Coronavirus ◽  
Nucleocapsid Proteins

ABSTRACT Recombinant severe acute respiratory syndrome (SARS) nucleocapsid and spike protein-based immunoglobulin G immunoassays were developed and evaluated. Our assays demonstrated high sensitivity and specificity to the SARS coronavirus in sera collected from patients as late as 2 years postonset of symptoms. These assays will be useful not only for routine SARS coronavirus diagnostics but also for epidemiological and antibody kinetic studies.

scholarly journals Longitudinal Profile of Immunoglobulin G (IgG), IgM, and IgA Antibodies against the Severe Acute Respiratory Syndrome (SARS) Coronavirus Nucleocapsid Protein in Patients with Pneumonia Due to the SARS Coronavirus

2004 ◽  
Vol 11 (4) ◽  
pp. 665-668 ◽  
Author(s):  
Patrick C. Y. Woo ◽  
Susanna K. P. Lau ◽  
Beatrice H. L. Wong ◽  
Kwok-hung Chan ◽  
Chung-ming Chu ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Indirect Immunofluorescence ◽  
Immunoglobulin G ◽  
Nucleocapsid Protein ◽  
Baseline Level ◽  
Immunofluorescence Assay ◽  
Indirect Immunofluorescence Assay ◽  
Enzyme Linked Immunosorbent Assay ◽  
Sars Coronavirus ◽  
Iga Antibodies

ABSTRACT By using a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein-based enzyme-linked immunosorbent assay (ELISA) and serum specimens serially collected (from day 0 to day 240 after symptom onset) from patients with pneumonia due to SARS-CoV, we analyzed the longitudinal profiles of immunoglobulin G (IgG), IgM, and IgA antibodies against the SARS-CoV nucleocapsid protein in patients with pneumonia due to SARS-CoV. For IgG, the median optical density at 450 nm (OD450) turned positive at day 17 and a biphasic response was observed. At day 240, all patients were still positive for anti-nucleocapsid protein IgG antibody. For IgM, the median OD450 turned positive at day 20.5, peaked at about day 80, and fell to below the baseline level at about day 180. At day 240, 36% of the patients were still positive for anti-nucleocapsid protein IgM antibody. For IgA, the median OD450 turned positive at day 17, peaked at about day 50, and fell to below the baseline level at about day 180. At day 240, 36% of the patients were still positive for anti-nucleocapsid protein IgA antibody. The time of seroconversion detected by the recombinant SARS-CoV nucleocapsid protein-based ELISA and that detected by indirect immunofluorescence assay were similar. The median times of seroconversion for IgG, IgM, and IgA detected by the indirect immunofluorescence assay were 17 days (17 days by ELISA), 16.5 days (20.5 days by ELISA), and 17.5 days (17 days by ELISA), respectively, after disease onset. One, four, and one of the six patients who died did not produce any IgG, IgM, and IgA antibodies against the nucleocapsid protein of SARS-CoV, respectively, although these antibodies were detected in all six patients by the indirect immunofluorescence assay. Further studies should be performed to see whether SARS-CoV nucleocapsid protein antibody positivity has any prognostic significance.

scholarly journals Absence of infection in asymptomatic contacts of index SARS case in France

2006 ◽  
Vol 11 (1) ◽  
pp. 9-10 ◽  
Author(s):  
S Le Vu ◽  
Y Yazdanpanah ◽  
D Bitar ◽  
J Emmanuelli ◽  
I Bonmarin ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Blood Sample ◽  
Immunoglobulin G ◽  
Case Definition ◽  
Serological Survey ◽  
Sars Coronavirus ◽  
Antibody Testing ◽  
First Case ◽  
Infectious Stage ◽  
High Infectivity

The first case of severe acute respiratory syndrome (SARS) in France was diagnosed in March 2003. We conducted a serological survey to assess whether or not asymptomatic persons who had been in contact with this patient during his infectious stage had been infected. They were interviewed and asked to provide a blood sample for SARS coronavirus immunoglobulin G antibody testing. Despite the likely high infectivity of the SARS patient, no asymptomatic SARS infection was found in any of the 37 contacts included. These findings support a SARS case definition that is essentially based on clinical and epidemiological assessment, should SARS re-emerge.

scholarly journals Recombinant Truncated Nucleocapsid Protein as Antigen in a Novel Immunoglobulin M Capture Enzyme-Linked Immunosorbent Assay for Diagnosis of Severe Acute Respiratory Syndrome Coronavirus Infection

2007 ◽  
Vol 14 (2) ◽  
pp. 146-149 ◽  
Author(s):  
Fuxun Yu ◽  
Mai Quynh Le ◽  
Shingo Inoue ◽  
Futoshi Hasebe ◽  
Maria del Carmen Parquet ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Immunosorbent Assay ◽  
Nucleocapsid Protein ◽  
Seroconversion Rate ◽  
Disease Onset ◽  
Immunoglobulin M ◽  
Antibody Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igm Antibody ◽  
Specificity And Sensitivity

ABSTRACT We report the development of an immunoglobulin M (IgM) antibody capture enzyme-linked immunosorbent assay (MAC-ELISA) for severe acute respiratory syndrome coronavirus (SARS-CoV) by using recombinant truncated SARS-CoV nucleocapsid protein as the antigen. The newly developed MAC-ELISA had a specificity and sensitivity of 100% as evaluated by using sera from healthy volunteers and patients with laboratory-confirmed SARS. Using serial serum samples collected from SARS patients, the times to seroconversion were determined by IgM antibody detection after SARS-CoV infection. The median time to seroconversion detection was 8 days (range, 5 to 17 days) after disease onset, and the seroconversion rates after the onset of illness were 33% by the first week, 97% by the second week, and 100% by the third week. Compared with the results of our previous report on the detection of IgG, the median seroconversion time by IgM detection was 3 days earlier and the seroconversion rate by the second week after the illness for IgM was significantly higher than by IgG assay. Our results indicating that the IgM response appears earlier than IgG after SARS-CoV infection in consistent with those for other pathogens. Our newly developed MAC-ELISA system offers a new alternative for the confirmation of SARS-CoV infection.

scholarly journals Kinetics of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibodies in 271 Laboratory-Confirmed Cases of SARS

2004 ◽  
Vol 11 (4) ◽  
pp. 792-794 ◽  
Author(s):  
Zhongping He ◽  
Qingming Dong ◽  
Hui Zhuang ◽  
Shujing Song ◽  
Guoai Peng ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Enzyme Immunoassay ◽  
Immunoglobulin G ◽  
Immunofluorescence Assay ◽  
Sars Coronavirus ◽  
Specific Antibodies ◽  
Kinetics Of

ABSTRACT The sensitivities and specificities of an immunofluorescence assay and an enzyme immunoassay for detection of antibodies specific for severe acute respiratory syndrome coronavirus (SARS-CoV) were compared for 148 laboratory-confirmed SARS cases. The appearance and persistence of SARS-CoV-specific antibodies were assessed, with immunoglobulin G detected in 59% of samples collected within 14 days and persisting for 60 to 95 days after the onset of illness.

scholarly journals SARS-CoV-2 Seroprevalence among Healthcare Workers in General Hospitals and Clinics in Japan

2021 ◽  
Vol 18 (7) ◽  
pp. 3786
Author(s):  
Tatsuya Yoshihara ◽  
Kazuya Ito ◽  
Masayoshi Zaitsu ◽  
Eunhee Chung ◽  
Izumi Aoyagi ◽  
...  
Keyword(s):  
Public Health ◽  
Social Support ◽  
General Population ◽  
Severe Acute Respiratory Syndrome ◽  
Immunoglobulin G ◽  
Health Problem ◽  
Healthcare Workers ◽  
Public Health Problem ◽  
General Hospitals ◽  
Second Wave

Coronavirus disease 2019 (COVID-19) has become a serious public health problem worldwide. In general, healthcare workers are considered to be at higher risk of COVID-19 infection. However, the prevalence of COVID-19 among healthcare workers in Japan is not well characterized. In this study, we aimed to examine the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among 2160 healthcare workers in hospitals and clinics that are not designated to treat COVID-19 patients in Japan. The prevalence of SARS-CoV-2 immunoglobulin G was 1.2% in August and October 2020 (during and after the second wave of the pandemic in Japan), which is relatively higher than that in the general population in Japan (0.03–0.91%). Because of the higher risk of COVID-19 infection, healthcare workers should be the top priority for further social support and vaccination against SARS-CoV-2.

scholarly journals Dynamic changes of acquired maternal SARS-CoV-2 IgG in infants

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Xia Wang ◽  
Pu Yang ◽  
Junwen Zheng ◽  
Pin Liu ◽  
Cong Wei ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Pregnant Women ◽  
Dynamic Characteristics ◽  
Perinatal Infection ◽  
Serum Antibodies ◽  
Dynamic Changes ◽  
Transfer Rates ◽  
Positive Rate ◽  
Igg Level ◽  
Maternal Igg

AbstractAt present, there are still ambiguous reports about the perinatal infection of infants born to mothers infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The dynamic characteristics of infantile serum antibodies born to mother with SARS-CoV-2 has not been well described. In this study, we analyzed the seroconversion of 27 newborns born to 26 pregnant women infected with SARS-CoV-2. The SARS-CoV-2 IgG positive rate of parturient was 80.8%, and half of their infants obtained maternal IgG. IgG transfer rates were 18.8% and 81.8% in those infants whose mother infected less and more than 2 weeks before delivery. In the first two months of life, the IgG level of infants dropped sharply to one tenth of that at birth. These results suggest that maternal SARS-CoV-2 IgG provides limited protection for infants.

scholarly journals Comparison of Five Serological Assays for the Detection of SARS-CoV-2 Antibodies

Diagnostics ◽  
2021 ◽  
Vol 11 (1) ◽  
pp. 78
Author(s):  
Anja Dörschug ◽  
Julian Schwanbeck ◽  
Andreas Hahn ◽  
Anke Hillebrecht ◽  
Sabine Blaschke ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Blood Donor ◽  
Immunoglobulin G ◽  
The Other ◽  
Specific Antibodies ◽  
Diagnostic Assays ◽  
Immunoglobulin Class ◽  
Corona Virus ◽  
Immunoglobulin Subclass

Serological assays can contribute to the estimation of population proportions with previous immunologically relevant contact with the Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) virus. In this study, we compared five commercially available diagnostic assays for the diagnostic identification of SARS-CoV-2-specific antibodies. Depending on the assessed immunoglobulin subclass, recorded sensitivity ranged from 17.0% to 81.9% with best results for immunoglobulin G. Specificity with blood donor sera ranged from 90.2% to 100%, with sera from EBV patients it ranged from 84.3% to 100%. Agreement from fair to nearly perfect was recorded depending on the immunoglobulin class between the assays, the with best results being found for immunoglobulin G. Only for this immunoglobulin class was the association between later sample acquisition times (about three weeks after first positive PCR results) and positive serological results in COVID-19 patients confirmed. In conclusion, acceptable and comparable reliability for the assessed immunoglobulin G-specific assays could be shown, while there is still room for improvement regarding the reliability of the assays targeting the other immunoglobulin classes.

Sign in / Sign up

Export Citation Format

Share Document